Abstract
The putative satiety agent human satietin (h-SAT) once thought to be homogenous has been separated by high-performance liquid chromatography (HPLC) into components designated peak A (P-A, 53%/w) and Peak B (P-B, 47%/w); P-B contains a putative satiety agent. In Experiment 1, male Sprague-Dawley rats were divided into six ( n = 9–11) groups (Grps) and ICV infused: Grp 1, artificial cerebrospinal fluid (a-CSF), 10 μl/rat; Grp 2, albumin (ALB), 53 μg/rat; Grp 3, semipurified (sp) h-SAT (parent compound), 100 μg/rat; Grp 4, P-A, 53 μg/rat; Grp 5, P-B, 47 μg/rat; and Grp 6, P-A+B, 53 + 47 μg/rat, respectively. Compared to Grp 1, food intake, the first day postinfusion, was suppressed in Grp 3 ( p < 0.01) and equally attenuated ( p < 0.06) in Grps 5 and 6. Body weight remained suppressed ( p < 0.05) in Grps 3, 5, and 6 for 3 days and in Grps 3 and 6 ( p < 0.05) for an additional 3 days; Grps 2 and 4 did not differ from Grp 1. These data show P-B suppresses food intake comparably to P-A+B and causes a prolonged weight loss. In Experiment 2, sph-SAT and a recombination of P-A and P-B was tested for aversiveness using the two-bottle test. Both sph-SAT and P-A + B significantly suppressed food intake, but only sph-SAT was found to be aversive. These data show that most likely during HPLC processing of sph-SAT an aversive component was lost.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
